Last reviewed · How we verify

NCT05528211

Safety and Efficacy of Emergent TAVI in Patients With Severe AS

Not yet recruiting Last updated 6 September 2022
What this trial tests

trial in Aortic Valve Stenosis in 10 participants. Not yet recruiting.

Timeline
1 September 2022
Primary endpoint
1 September 2023
1 November 2028

Quick facts

Lead sponsorQilu Hospital of Shandong University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment10
Start date1 September 2022
Primary completion1 September 2023
Estimated completion1 November 2028

Conditions studied

Sponsor

Qilu Hospital of Shandong University

Who can join

Eligibility, any sex, with Aortic Valve Stenosis or Transcatheter Aortic Valve Implantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-centre, prospective, observational cohort study focusing on of patients suffering severe aortic valve stenosis (AS) undergoing emergent transcatheter aortic valve implantation (TAVI). AS patients undergoing emergent TAVI always have complicated clinical situations. Therefore, the aims of the study are to collect the incidence and outcomes of emergent TAVI in patients with severe symptomatic AS, to assess the safety and effectiveness of emergency TAVI system for severe AS, and to describe a more practical evidence of emergency TAVI system in severe AS patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Valve Stenosis

Currently open trials in the same condition.

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05528211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing